# CareCloud, Inc.: Form 10-Q for the period ended Sep 30, 2018

- Company: [CareCloud, Inc.](/companies/ccld.md) (CIK 1582982)
- Form: 10-Q
- Filed: 2018-11-07
- Accepted by EDGAR: Nov 7, 2018, 16:31 ET
- Period: 2018-09-30
- Accession: 0001493152-18-015353
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1582982/000149315218015353/form10-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1582982/000149315218015353/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-07-01 to 2018-09-30 | $17.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2018-01-01 to 2018-09-30 | $34.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Research and development | 3 months, 2018-07-01 to 2018-09-30 | $263.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2018-01-01 to 2018-09-30 | $768.5k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2018-07-01 to 2018-09-30 | −$1.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2018-01-01 to 2018-09-30 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2018-07-01 to 2018-09-30 | −$250.1k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2018-01-01 to 2018-09-30 | −$151.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2018-07-01 to 2018-09-30 | −$1.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2018-01-03 to 2018-09-30 | −$1.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-07-01 to 2018-09-30 | −$0.25 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2018-01-01 to 2018-09-30 | −$0.40 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 9 months, 2018-01-01 to 2018-09-30 | $4.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2018-01-01 to 2018-09-30 | $743.1k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | at 2018-09-30 | $1.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-09-30 | $13.8m | us-gaap:AssetsCurrent |
| Total assets | at 2018-09-30 | $36.1m | us-gaap:Assets |
| Current liabilities | at 2018-09-30 | $8.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-09-30 | $8.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2018-09-30 | $27.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 45,831 characters.

The following is a discussion of our consolidated financial condition and results of operations for the three and nine months ended September 30, 2018 and 2017 and other factors that are expected to affect our prospective financial condition. The following discussion and analysis should be read together with our Condensed Consolidated Financial Statements and related notes beginning on page 4 of this Quarterly Report on Form 10-Q.

Some of the statements set forth in this section are forward-looking statements relating to our future results of operations. Our actual results may vary from the results anticipated by these statements. Please see “*Forward-Looking Statements”* on page 2 of this Quarterly Report on Form 10-Q.

### Overview

Medical Transcription Billing, Corp., together with its consolidated subsidiaries (the “Company”), is a healthcare information technology company that provides a suite of proprietary web-based solutions and business services to healthcare providers. Our integrated Software-as-a-Service (“SaaS”) platform and business services are designed to help our clients increase revenues, streamline workflows and make better business and clinical decisions, while reducing administrative burdens and operating costs. These solutions and services include:

- Revenue cycle management (“RCM”) services, which include end-to-end medical billing, eligibility, analytics, and related services, all of which can be provided either with our technology platform or through a third-party system;
- Proprietary, healthcare IT solutions, which is part of our RCM services, including:
- Electronic health records (“EHR”), which are easy to use, integrated with our business services and allow our healthcare provider clients to reduce paperwork and qualify for incentives;
- Practice management software and related tools, which support our clients’ day-to-day business operations and workflows;
- Mobile Health (“mHealth”) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services;
- Healthcare claims clearinghouse, which enables our clients to electronically scrub and submit claims to, and process payments from, insurance companies; and
- Business intelligence, customized applications, interfaces and a variety of other technology solutions that support our healthcare clients;
- Comprehensive practice management services, which are offered under long-term management service agreements pursuant to which we provide certain practices with the administrative support, facilities, supplies, equipment, marketing, RCM, accounting, and other non-clinical services needed to efficiently operate their practices; and
- Group purchasing services which include our negotiation of discounts with pharmaceutical manufacturers and the extension of those discounts to our physician members, which is part of our RCM services.

We are able to deliver our industry-leading solutions at very competitive prices because we leverage a combination of our proprietary software, which automates our workflows and increases efficiency, together with our team of experienced health industry experts throughout the United States, who are supported by our highly educated and specialized offshore workforce of approximately 2,000 team members at labor costs that we believe are approximately one-tenth the cost of comparable U.S. employees. Our unique business model has also allowed us to become a leading consolidator in our industry sector, in which we have gained a reputation for being able to acquire and transform distressed competitors into profitable operations of MTBC.

During July 2018, the Company acquired substantially all of the revenue cycle management, practice management and group purchasing assets of Orion Healthcorp, Inc. and 13 of its affiliates (together “Orion”). The Company paid $12.6 million in cash for the acquisition. This acquisition expanded the scope of our offerings to include additional niche hospital solutions, a service that negotiates vaccine discounts with pharmaceutical manufacturers and then extends those vaccine discounts to physician members, and a service that provides end-to-end practice management services to physician practices under multi-decade management service agreements.

Adoption of our RCM solutions requires little or no upfront expenditure by a practice. Additionally, for most of our solutions and customers, our financial performance is linked directly to the financial performance of our clients because the vast majority of our revenues are based on a percentage of our clients’ collections. The standard fee for our complete, integrated, end-to-end solution is among the lowest in the industry. We currently provide services to more than 12,000 providers, (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services) practicing in approximately 1,800 independent medical practices and hospitals.

Our offshore operations in Pakistan and Sri Lanka accounted for approximately 24% and 29% of total expenses for the nine months ended September 30, 2018 and 2017, respectively. A significant portion of those foreign expenses were personnel-related costs (approximately 79% for the both nine months ended September 30, 2018 and 2017). Because personnel-related costs are significantly lower in Pakistan and Sri Lanka than in the U.S. and many other offshore locations, we believe our offshore operations give us a competitive advantage over many industry participants. We are able to achieve significant cost reductions as leverage technology to reduce manual work and strategically transition a portion of the remaining manual tasks to our highly-specialized, cost-efficient team in the U.S., Pakistan and Sri Lanka.

### Key Performance Measures

We consider numerous factors in assessing our performance. Key performance measures used by management, including adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share, are non-GAAP financial measures, which we believe better enable management and investors to analyze and compare the underlying business results from period to period.

These non-GAAP financial measures should not be considered in isolation, or as a substitute for or superior to, financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Moreover, these non-GAAP financial measures have limitations in that they do not reflect all the items associated with the operations of our business as determined in accordance with GAAP. We compensate for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis, and we provide reconciliations from the most directly comparable GAAP financial measures to the non-GAAP financial measures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share provide an alternative view of performance used by management and we believe that an investor’s understanding of our performance is enhanced by disclosing these adjusted performance measures.

Adjusted EBITDA excludes the following elements which are included in GAAP net income (loss):

- Income tax (benefit) expense or the cash requirements to pay our taxes;
- Interest expense, or the cash requirements necessary to service interest on principal payments, on our debt;
- Foreign currency gains and losses and other non-operating expenditures;
- Stock-based compensation expense and cash-settled awards, based on changes in the stock price;
- Depreciation and amortization charges;
- Integration costs, such as severance amounts paid to employees from acquired businesses, transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees, exit costs related to contractual agreements and restructuring charges arising from discontinued facilities and operations; and
- Changes in contingent consideration.

24

Set forth below is a presentation of our adjusted EBITDA for the three and nine months ended September 30, 2018 and 2017:

*($ in thousands)*

|  | Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | $17,045 | $7,514 | $34,035 | $23,519 |
| GAAP net loss | $(1,832) | $(980) | $(1,562) | $(5,382) |
| (Benefit) provision for income taxes | (250) | 65 | (152) | 192 |
| Net interest expense | 80 | 673 | 193 | 1,229 |
| Foreign exchange / other expense | 227 | (24) | (105) | (34) |
| Stock-based compensation expense | 987 | 126 | 1,524 | 334 |
| Depreciation and amortization | 822 | 664 | 1,973 | 3,637 |
| Integration, transaction and restructuring costs | 806 | 85 | 1,457 | 636 |
| Change in contingent consideration | 25 | - | 68 | 151 |
| Adjusted EBITDA | **$865** | **$609** | **$3,396** | **$763** |

Adjusted operating income and adjusted operating margin exclude the following elements which are included in GAAP operating income (loss):

- Stock-based compensation expense and cash-settled awards, based on changes in the stock price;
- Amortization of purchased intangible assets;
- Integration costs, such as severance amounts paid to employees from acquired businesses, transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees, exit costs related to contractual agreements, and restructuring charges arising from discontinued facilities and operations; and
- Changes in contingent consideration.

Set forth below is a presentation of our adjusted operating income and adjusted operating margin, which represents adjusted operating income as a percentage of net revenue, for the three and nine months ended September 30, 2018 and 2017:

*($ in thousands)*

|  | Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | $17,045 | $7,514 | $34,035 | $23,519 |
| GAAP net loss | $(1,832) | $(980) | $(1,562) | $(5,382) |
| (Benefit) provision for income taxes | (250) | 65 | (152) | 192 |
| Net interest expense | 80 | 673 | 193 | 1,229 |
| Other expense (income) - net | 219 | (32) | (151) | (107) |
| GAAP operating loss | (1,783) | (274) | (1,672) | (4,068) |
| GAAP operating margin | (10.5)% | (3.6)% | (4.9)% | (17.3)% |
| Stock-based compensation expense | 987 | 126 | 1,524 | 334 |
| Amortization of purchased intangible assets | 559 | 419 | 1,257 | 2,881 |
| Integration, transaction and restructuring costs | 806 | 85 | 1,457 | 636 |
| Change in contingent consideration | 25 | - | 68 | 151 |
| Non-GAAP adjusted operating income | **$594** | **$356** | **$2,634** | **$(66)** |
| Non-GAAP adjusted operating margin | 3.5% | 4.7% | 7.7% | (0.3)% |

25

Adjusted net income and adjusted net income per share exclude the following elements which are included in GAAP net income (loss):

- Foreign currency gains and losses and other non-operating expenditures;
- Stock-based compensation expense and cash-settled awards, based on changes in the stock price;
- Amortization of purchased intangible assets;
- Integration costs, such as severance amounts paid to employees from acquired businesses, transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees, exit costs related to contractual agreements, and restructuring charges arising from discontinued facilities and operations;
- Changes in contingent consideration; and
- Income tax (benefit) expense resulting from the amortization of goodwill related to our acquisitions.

No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes. The following table shows our reconciliation of GAAP net loss to non-GAAP adjusted net income for the three and nine months ended September 30, 2018 and 2017:

*($ in thousands)*

|  | Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| GAAP net loss | $(1,832) | $(980) | $(1,562) | $(5,382) |
| Foreign exchange / other expense | 227 | (24) | (105) | (34) |
| Stock-based compensation expense | 987 | 126 | 1,524 | 334 |
| Amortization of purchased intangible assets | 559 | 419 | 1,257 | 2,881 |
| Integration, transaction and restructuring costs | 806 | 85 | 1,457 | 636 |
| Change in contingent consideration | 25 | - | 68 | 151 |
| Income tax (benefit) expense related to goodwill | (265) | 55 | (187) | 165 |
| Non-GAAP adjusted net income | **$507** | **$(319)** | **$2,452** | **$(1,249)** |

Set forth below is a reconciliation of our non-GAAP adjusted net income per share to our GAAP net loss attributable to common shareholders, per share:

|  | Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| GAAP net loss attributable to common shareholders, per share | $(0.25) | $(0.14) | $(0.40) | $(0.62) |
| Impact of preferred stock dividend | 0.10 | 0.05 | 0.27 | 0.15 |
| Net loss per end-of-period share | (0.15) | (0.09) | (0.13) | (0.47) |
| Foreign exchange / other expense | 0.02 | 0.00 | (0.01) | 0.00 |
| Stock-based compensation expense | 0.08 | 0.01 | 0.13 | 0.03 |
| Amortization of purchased intangible assets | 0.04 | 0.04 | 0.11 | 0.25 |
| Integration, transaction and restructuring costs | 0.07 | 0.01 | 0.12 | 0.06 |
| Change in contingent consideration | 0.00 | - | 0.01 | 0.01 |
| Income tax (benefit) expense related to goodwill | (0.02) | 0.00 | (0.02) | 0.01 |
| Non-GAAP adjusted net income per share | **$0.04** | **$(0.03)** | **$0.21** | **$(0.11)** |
| End-of-period shares | 11,829,758 | 11,530,591 | 11,829,758 | 11,530,591 |

For purposes of determining non-GAAP adjusted net income per share, the Company used the number of common shares outstanding at the end of September 30, 2018 and 2017. Non-GAAP adjusted net income per share does not take into account dividends paid on our preferred stock. No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per common share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes.

### Key Metrics

In addition to the line items in our consolidated financial statements, we regularly review the following metrics. We believe information on these metrics is useful for investors to understand the underlying trends in our business.

***Providers and Practices Served:*** As of September 30, 2018, we provided services to an estimated universe of more than 12,000 providers (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services), representing approximately 1,800 independent medical practices and hospitals. In addition, we served approximately 200 clients who were not medical practices, but are service organizations who serve the healthcare community. As of September 30, 2017, we served approximately 2,600 providers representing approximately 740 practices. The foregoing numbers include clients leveraging any of our products or services and are based in part upon estimates in cases where the precise number of practices or providers is unknown.

### Sources of Revenue

*Revenue:* We primarily derive our revenues from revenue cycle management services, typically billed as a percentage of payments collected by our customers. This fee includes RCM as well as the ability to use our EHR and practice management software as part of the bundled fee. All of these services are considered revenue cycle management revenue. These payments accounted for approximately 69% and 90% of our revenues during the three months ended September 30, 2018 and 2017 and 79% and 90% for the nine months ended September 30, 2018 and 2017, respectively. Other services, including printing and mailing operations and professional services represented approximately 5% of revenues for each the three and nine months ended September 30, 2018 and 2017.

Starting with our acquisition of Orion on July 1, 2018, we earned approximately 19% of our revenue from practice management services during the three months ended September 30, 2018. This revenue represents fees based on our actual costs plus a percentage of the operating profit. Also commencing July 1, 2018, we earned approximately 3% of our revenue during the three months ended September 30, 2018 from group purchasing services.

### Operating Expenses

*Direct Operating Costs.* Direct operating cost consists primarily of salaries and benefits related to personnel who provide services to our customers, claims processing costs, costs to operate the three managed practices, including facilities, supplies, insurance and other direct costs related to our services. Costs associated with the implementation of new customers are expensed as incurred. The reported amounts of direct operating costs do not include depreciation and amortization, which are broken out separately in the condensed consolidated statements of operations.

*Selling and Marketing Expense.* Selling and marketing expense consists primarily of compensation and benefits, commissions, travel and advertising expenses.

*Research and Development Expense.* Research and development expense consists primarily of personnel-related costs and third-party contractor costs.

*General and Administrative Expense.* General and administrative expense consists primarily of personnel-related expense for administrative employees, including compensation, benefits, travel, occupancy and insurance, software license fees and outside professional fees.

*Contingent Consideration.* Contingent consideration represents the portion of consideration payable to the sellers of some of our acquisitions, the amount of which is based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period.

*Depreciation and Amortization Expense.* Depreciation expense is charged using the straight-line method over the estimated lives of the assets ranging from three to ten years. Amortization expense is charged on either an accelerated or on a straight-line basis over a period of three or four years for most intangible assets acquired in connection with acquisitions including those intangibles related to the group purchasing services. Amortization expense related to the value of our practice management clients, whose contracts have 20 years remaining and whose terms provide limited opportunities for cancellation, is amortized on a straight-line basis over a period of twelve years.

*Interest and Other Income (Expense).* Interest expense consists primarily of interest costs related to our working capital line of credit, term loans and amounts due in connection with acquisitions, offset by interest income. Other income (expense) results primarily from foreign currency transaction gains (losses) and income earned from temporary cash investments.

*Income Tax.* In preparing our condensed consolidated financial statements, we estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred income tax assets and liabilities. Although the Company is forecasting a return to profitability, it incurred cumulative losses, which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all deferred tax assets as of September 30, 2018 and December 31, 2017.

On December 22, 2017, the Tax Cuts and Jobs Act (the “Act”) was enacted. Effective January 1, 2018, among other changes, the Act (a) reduces the U.S. federal corporate tax rate to 21 percent, provides for a deemed repatriation and taxation at reduced rates on historical earnings (a “Transition Tax”) of certain non-US subsidiaries owned by U.S. companies and establishes new mechanisms to tax such earnings going forward. For the Transition Tax, further information was required to finalize the estimated amount of accumulated foreign earnings as well as to validate the amount of earnings represented by the aggregate foreign cash position as defined in the Tax Act. We completed our analysis during the third quarter of 2018. During the nine months ended September 30, 2018, no additional impact from the enactment of the Act was identified during the measurement period as provided in Staff Accounting Bulletin 118.

The Act includes a provision effective January 1, 2018 for a global intangible low-taxed income (“GILTI”) tax. Companies can either account for the GILTI inclusion in the period in which they are incurred or establish deferred tax liabilities for the expected future taxes associated with GILTI. The Company elected to record the GILTI provisions as they are incurred each period.

### Critical Accounting Policies and Estimates

We prepare our condensed consolidated financial statements in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions about future events, and apply judgments that affect the reported amounts of assets, liabilities, revenue, expense and related disclosures. We base our estimates, assumptions and judgments on historical experience, current trends and various other factors that we believe to be reasonable under the circumstances. The accounting estimates used in the preparation of our condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. On a regular basis, we review our accounting policies, estimates, assumptions and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. The methods, estimates and judgments that we use in applying our accounting policies have a significant impact on our results of operations.

Critical accounting policies are those policies used in the preparation of our condensed consolidated financial statements that require management to make difficult, subjective, or complex adjustments, and to make estimates about the effect of matters that are inherently uncertain. As a result of our adoption of the new revenue recognition standard on January 1, 2018, we re-assessed the estimates, assumptions, and judgments that are most critical in our recognition of revenue.

We account for revenue in accordance with ASC 606, *Revenue from Contracts with Customers*. Our revenue recognition policies require us to make significant judgments and estimates, particularly as it relates to revenue cycle management and group purchasing revenue. Under ASC 606, certain significant accounting estimates, such as payment-to-charge ratios, effective billing rates and the estimated contractual payment periods are required to measure the revenue cycle management revenue. To measure group purchasing services revenue, we need to estimate the number of providers purchasing vaccines and the amount and timing of those purchases. We analyze various factors including, but not limited to, contractual terms and conditions, the credit-worthiness of our customers and our pricing policies. Changes in judgment on any of the above factors could materially impact the timing and amount of revenue recognized in a given period.

#### Revenue cycle management services:

Most of our revenue cycle management contracts contain variable consideration and we estimate the variable consideration which we expect to be entitled to over the contractual period associated with our revenue cycle management contracts, which begins no earlier than go-live and recognize the fees over the term. When a contract includes variable consideration, we evaluate the estimate of the variable consideration to determine whether the estimate needs to be constrained; therefore, we include the variable consideration in the transaction price only to the extent that it is probable that a significant reversal of the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. For the majority of our revenue cycle management contracts, the total contractual price is variable because our obligation is to process an unknown quantity of transactions, as and when requested by our customers, over the contract period. We allocate the variable price to each claim processed using the time-series concept and recognize revenue based on the most likely amount of consideration to which we will be entitled to, which is generally the amount we will have the right to invoice. Estimates to determine the variable consideration such as payment to charge ratios, effective billing rates, and the estimated contractual payment periods are updated at each reporting date.

#### Practice management services:

We estimate the variable consideration which we expect to be entitled to for the group purchasing services based upon anticipated shipments to the medical providers enrolled in the program, seasonality and the changes in the number of providers. The estimate of variable consideration includes adjusting historical data for anticipated changes from prior periods. When reviewing our estimates, in order to ensure that our estimates do not pose a risk of significantly overstating our revenue in any reporting period, we will apply constraints, when appropriate, to certain estimates around our variable consideration. Variable consideration estimates are updated at each reporting period.

Although we believe that our approach to estimates and judgements is reasonable, actual results could differ, and we may be exposed to increases or decreases in revenue that could be material. Our estimates of variable consideration may prove to be inaccurate, in which case we may have understated or overstated the revenue recognized in an accounting period. The amount of variable consideration recognized to date that remains subject to estimation is included within the contract asset on the condensed consolidated balance sheet.

Revenue is recognized as the performance obligations are satisfied. We derive revenue from seven primary sources: revenue cycle management services, practice management services, professional services, ancillary services, group purchasing services, printing and mailing services, and clearinghouse and EDI (electronic data interchange) services. All of our revenue arrangements are based on contracts with customers. Most of our contracts with customers contain single performance obligations, although certain contracts do contain multiple performance obligations. We account for individual performance obligations separately if they are distinct. For contracts where we provide multiple services such as where we perform multiple ancillary services, each service represents its own performance obligation. Selling or transaction prices are based on the contractual price for the service.

Other than the additional estimates as a result of ASC 606 discussed above, there have been no material changes in our critical accounting policies and estimates from those described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 7, 2018.

### Results of Operations

The following table sets forth our consolidated results of operations as a percentage of total revenue for the periods shown:

|  | Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net revenue | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating expenses: |  |  |  |  |
| Direct operating costs | 71.1% | 55.5% | 61.5% | 57.8% |
| Selling and marketing | 2.7% | 3.0% | 3.4% | 3.6% |
| General and administrative | 30.1% | 32.9% | 31.7% | 35.0% |
| Change in contingent consideration | 0.1% | 0.0% | 0.2% | 0.6% |
| Research and development | 1.5% | 3.3% | 2.3% | 3.6% |
| Depreciation and amortization | 4.8% | 8.8% | 5.8% | 15.5% |
| Restructuring charges | 0.0% | 0.0% | 0.0% | 1.2% |
| Total operating expenses | 110.3% | 103.5% | 104.9% | 117.3% |
| Operating loss | (10.3)% | (3.5)% | (4.9)% | (17.3)% |
| Interest expense - net | 0.5% | 9.0% | 0.6% | 5.2% |
| Other (expense) income - net | (1.3)% | 0.4% | 0.4% | 0.5% |
| Loss before income taxes | (12.1)% | (12.1)% | (5.1)% | (22.0)% |
| Income tax (benefit) provision | (1.5)% | 0.9% | (0.4)% | 0.8% |
| Net loss | (10.6)% | (13.0)% | (4.7)% | (22.8)% |

### Comparison of the three and nine months ended September 30, 2018 and 2017

|  | Three Months Ended September 30, 2018 | 2017 | Change Amount | Percent | Nine Months Ended September 30, 2018 | 2017 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $17,044,526 | $7,513,592 | $9,530,934 | 127% | $34,034,788 | $23,518,416 | $10,516,372 | 45% |

*Revenue.* Total revenue of $17.0 million and $34.0 million for the three and nine months ended September 30, 2018 increased by $9.5 million or 127% and $10.5 million or 45% from revenue of $7.5 million and $23.5 million for the three and nine months ended September 30, 2017, respectively. Revenue for the three and nine months ended September 30, 2018 includes approximately $9.4 million from the Orion acquisition. Of this amount, $5.6 million relates to RCM clients and other revenue streams, $3.3 million relates to practice management services and $477,000 relates to group purchasing services. Revenue for the three and nine months ended September 30, 2018 also includes approximately $36,000 and $149,000, respectively of revenue we acquired from the WMB acquisition.

|  | Three Months Ended September 30, 2018 | 2017 | Change Amount | Percent | Nine Months Ended September 30, 2018 | 2017 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Direct operating costs | $12,123,907 | $4,171,932 | $7,951,975 | 191% | $20,941,535 | $13,592,492 | $7,349,043 | 54% |
| Selling and marketing | 461,512 | 228,991 | 232,521 | 102% | 1,169,583 | 853,460 | 316,123 | 37% |
| General and administrative | 5,131,295 | 2,474,139 | 2,657,156 | 107% | 10,786,234 | 8,232,613 | 2,553,621 | 31% |
| Research and development | 263,717 | 249,045 | 14,672 | 6% | 768,517 | 843,294 | (74,777) | (9)% |
| Change in contingent consideration | 25,473 | - | 25,473 | 100% | 68,253 | 151,423 | (83,170) | (55)% |
| Depreciation | 188,893 | 156,237 | 32,656 | 21% | 484,881 | 484,429 | 452 | 0% |
| Amortization | 633,205 | 508,204 | 125,001 | 25% | 1,487,684 | 3,152,702 | (1,665,018) | (53)% |
| Restructuring charges | - | - | - | - | - | 275,628 | (275,628) | (100)% |
| Total operating expenses | $18,828,002 | $7,788,548 | $11,039,454 | 142% | $35,706,687 | $27,586,041 | $8,120,646 | 29% |

*Direct Operating Costs.* Direct operating costs of $12.1 million and $20.9 million for the three and nine months ended September 30, 2018, respectively, increased by $8.0 million or 191% and by $7.3 million or 54% from direct operating costs of $4.2 million and $13.6 million for the three and nine months ended September 30, 2017, respectively. During the three and nine months ended September 30, 2018, salary costs increased by $3.9 million and $3.5 million and outsourcing and processing costs increased by $1.8 million and $1.6 million, respectively. Facility costs increased by $440,000 and $346,000 for the three and nine months ended September 30, 2018, respectively. Medical supplies for the managed practices were $1.6 million for both the three and nine months ended September 30, 2018. The increase in the costs for the three and nine months ended September 30, 2018 were primarily related to the Orion acquisition.

*Selling and Marketing Expense.* Selling and marketing expense of $462,000 and $1.2 million for the three and nine months ended September 30, 2018 increased by $233,000 or 102% and $316,000 or 37% from selling and marketing expense of $229,000 and $853,000 for the three and nine months ended September 30, 2017, respectively. The increase was primarily due to increased marketing expenditures.

*General and Administrative Expense.* General and administrative expense of $5.1 million and $10.8 million for the three and nine months ended September 30, 2018 increased by $2.7 million or 107% and by $2.6 million or 31% compared to the same period in 2017. The increase in general and administrative expense for the three and nine months ended September 30, 2018 was primarily related to additional salaries, facility costs and professional fees as a result of the Orion acquisition.

*Research and Development Expense.* Research and development expense of $264,000 and $769,000 for the three and nine months ended September 30, 2018 increased by $15,000 or 6% and decreased by $75,000 or 9% from research and development expense of $249,000 and $843,000 for the three and nine months ended September 30, 2017, respectively.

*Contingent Consideration.* The change in contingent consideration of $25,000 and $68,000 during the three and nine months ended September 30, 2018, respectively and $151,000 during the nine months ended September 30, 2017 relates to the change in the fair value of the contingent consideration from acquisitions.

*Depreciation.* Depreciation of $189,000 for the three months ended September 30, 2018 increased by $33,000 or 21% from depreciation of $156,000 for the three months ended September 30, 2017 due to the property and equipment acquired as part of the Orion acquisition. Depreciation expense for the nine months ended September 30, 2018 was consistent with the comparable period in 2017.

*Amortization Expense.* Amortization expense of $633,000 and $1.5 million for the three and nine months ended September 30, 2018 increased by $125,000 and decreased by $1.7 million from amortization expense of $508,000 and $3.2 million for the three and nine months ended September 30, 2017, respectively. The increase for the three months ended September 30, 2018 was primarily related to the intangibles acquired from Orion acquisition. The decrease for the nine months ended September 30, 2018 resulted from the intangible assets acquired in connection with the Company’s 2014 and 2015 acquisitions becoming fully amortized, net of the increased amortization related to the acquired intangibles from the Orion acquisition.

*Restructuring Charges.* Restructuring charges during the nine months ended September 30, 2017 primarily represent employee severance costs, remaining lease and termination fees, disposal of property and equipment and professional fees associated with the closing of the operations in India and Poland. There were no similar costs incurred in 2018.

|  | Three Months Ended September 30, 2018 | 2017 | Change Amount | Percent | Nine Months Ended September 30, 2018 | 2017 | Change Amount | Percent |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Interest income | $24,544 | $5,446 | $19,098 | 351% | $59,768 | $13,598 | $46,170 | 340% |
| Interest expense | (104,872) | (678,103) | 573,231 | 85% | (253,120) | (1,242,672) | 989,552 | 80% |
| Other (expense) income - net | (218,721) | 32,494 | (251,215) | (773)% | 151,242 | 107,364 | 43,878 | 41% |
| Income tax provision | (250,072) | 65,000 | (315,072) | (485)% | (151,872) | 192,332 | (344,204) | (179)% |

*Interest Income.* Interest income of $25,000 and $60,000 for the three and nine months ended September 30, 2018 increased by $19,000 or 351% and $46,000 or 340% from interest income of $5,000 and $14,000 for the three and nine months ended September 30, 2017, respectively. The increase in interest income represents interest earned on temporary cash investments.

*Interest Expense.* Interest expense of $105,000 and $253,000 for the three and nine months ended September 30, 2018, respectively, decreased by $573,000 or 85% and $990,000 or 80% from interest expense of $678,000 and $1.2 million for the three and nine months ended September 30, 2017, respectively. This decrease was primarily due to interest costs on borrowings under our term loans and line of credit and amounts related to the MediGain transaction which were repaid during 2017. Interest expense includes the amortization of deferred financing costs which were $143,000 and $463,000 during the nine months ended September 30, 2018 and 2017, respectively.

*Other (Expense) Income - net.* Other (expense) income - net was ($219,000) and $151,000 for the three and nine months ended September 30, 2018, respectively, compared to other income - net of $32,000 and $107,000 for the three and nine months ended September 30, 2017, respectively. Other income is primarily foreign currency transaction gains (losses) resulting from transactions in foreign currencies other than the functional currency. These transaction gains and losses are recorded in the condensed consolidated statements of operations related to the recurring measurement and settlement of such transactions.

*Income Tax (Benefit) Provision.* There was a $250,000 and a $152,000 benefit for income taxes for the three and nine months ended September 30, 2018, respectively, compared to the provision for income taxes of $65,000 and $192,000 for the three and nine months ended September 30, 2017. Included in the tax provisions for the three and nine months ended September 30, 2018 is a $265,000 deferred Federal income tax benefit. As a result of the Company forecasting a tax loss for 2018, which has an indefinite life under the recent tax reform legislation, the Federal deferred tax liability was offset against the 2018 Federal net operating loss, resulting in a Federal net deferred income tax benefit of $265,000.

The current income tax provision for the three and nine months ended September 30, 2018 was approximately $15,000 and $35,000, respectively and primarily relates to state minimum taxes and foreign income taxes. The pre-tax loss was $2.1 million and $1.7 million for the three and nine months ended September 30, 2018, respectively, compared to a pre-tax loss of $915,000 and $5.2 million for the three and nine months ended September 30, 2017, respectively. Although the Company is forecasting a return to profitability, it incurred three years of cumulative losses which make realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance was recorded against all deferred tax assets at September 30, 2018 and 2017.

### Liquidity and Capital Resources

During the nine months ended September 30, 2018, there was positive cash flow from operations of approximately $4.7 million and on September 30, 2018 the Company had $1.3 million in cash, positive working capital of $5.7 million and no bank debt. During the three months ended September 30, 2018, cash flow provided by operations was $2.8 million. During the third quarter, the Company paid the remaining purchase price of $11.6 million for the Orion acquisition. The Company occasionally utilizes its revolving line of credit with SVB, but, as of September 30, 2018, there was no balance outstanding. SVB doubled the maximum availability on the line from $5 million to $10 million on September 20, 2018. During October 2018, the Company sold 600,000 additional shares of its Series A Preferred Stock raising net proceeds of approximately $13.4 million. During April 2018, the Company sold 420,000 shares of Series A Preferred Stock and raised net proceeds of approximately $9.4 million.

During October 2017, the Company repaid and closed its Opus credit facility and replaced it with a revolving line of credit with SVB. Borrowings under the SVB facility are based on 200% of repeatable revenue, reduced by an annualized attrition rate, as defined in the agreement. The entire facility is currently available to the Company. As of September 30, 2018, the Company was in compliance with all the covenants contained in the SVB credit agreement.

The following table summarizes our cash flows:

|  | Three Months Ended September 30, 2018 | 2017 | Nine Months Ended September 30, 2018 | 2017 |
| --- | ---: | ---: | ---: | ---: |
| Net cash provided by (used in) operating activities | $2,780,897 | $(618,752) | $4,748,502 | $(1,307,637) |
| Net cash used in investing activities | (11,966,685) | (359,773) | (13,343,115) | (704,988) |
| Net cash (used in) provided by financing activities | (1,427,406) | (1,990,525) | 5,776,640 | 1,400,885 |
| Effect of exchange rate changes on cash | 150,149 | (52,054) | (284,685) | (75,758) |
| Net decrease in cash | $(10,463,045) | $(3,021,104) | $(3,102,658) | $(687,498) |

32

The loss before income taxes was $2.1 million and $1.7 million for the three and nine months ended September 30, 2018, respectively, which included $822,000 and $2.0 million of non-cash depreciation and amortization, respectively.

During 2017, the Company raised a total of $18.4 million in net proceeds from a series of equity financings.

### Operating Activities

Cash provided by operating activities was $4.7 million during the nine months ended September 30, 2018, compared to cash used in operating activities of $1.3 million during the nine months ended September 30, 2017. The decrease in the net loss of $3.8 million included the following changes in non-cash items: a decrease in depreciation and amortization of $1.7 million, an increase in stock based compensation expense of $1.2 million, a change in the (benefit) provision for deferred income taxes of $352,000 and a decrease in interest accretion of $530,000.

The change in operating assets and liabilities increased by $3.9 million. Accounts receivable decreased by $902,000 for the nine months ended September 30, 2018, compared with a decrease of $438,000 for the nine months ended September 30, 2017. Accounts payable, accrued compensation and accrued expenses increased by $2.4 million for the nine months ended September 30, 2018 compared to a decrease of $1.8 million for the nine months ended September 30, 2017.

### Investing Activities

Cash used in investing activities during the nine months ended September 30, 2018 was $13.3 million, an increase of $12.6 million compared to $705,000 during the nine months ended September 30, 2017. During June 2018, the Company made a $1 million deposit in connection with the Orion acquisition. The balance of the purchase price of $11.6 million was paid during July. Capital expenditures were $743,000 and $500,000 for the nine months ended September 30, 2018 and 2017, respectively.

### Financing Activities

Cash provided by financing activities during the nine months ended September 30, 2018 and 2017 was $5.8 million and $1.4 million, respectively. Cash used in financing activities during the nine months of 2018 includes $329,000 of repayments for debt obligations and $2.8 million of preferred stock dividends. Cash used in financing activities for nine months ended September 30, 2017 included $7.6 million of repayment for debt obligations and $847,000 of preferred stock dividends. Average borrowings from our revolving line of credit were $1.4 million for the nine months ended September 30, 2017 and $210,000 during the nine months ended September 30, 2018. During the nine months ended September 30, 2018 and 2017, the Company sold an additional 420,000 and 610,000 shares of preferred stock raising approximately $9.4 million and $13.5 million of net proceeds, respectively.

### Contractual Obligations and Commitments

We have contractual obligations under our line of credit and related to contingent consideration in connection with the acquisitions made in 2015 and 2016. We also maintain operating leases for property and certain office equipment. We were in compliance with all SVB covenants as of September 30, 2018. For additional information, see Contractual Obligations and Commitments under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 7, 2018.

### Off-Balance Sheet Arrangements

As of September 30, 2018 and 2017, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special-purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. Other than our operating leases for office space, computer equipment and other property, we do not engage in off-balance sheet financing arrangements.

## Market risk

As filed, 175 characters.

We are a smaller reporting company as defined by 17 C.F.R. 229.10(f)(1) and are not required to provide information under this item, pursuant to Item 305(e) of Regulation S-K.

## Controls and procedures

As filed, 2,875 characters.

#### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, based on the 2013 framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2018 as required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures, as of September 30, 2018, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

#### Changes in Internal Control Over Financial Reporting

Beginning January 1, 2018, we implemented ASC 606, “*Revenue from Contracts with Customers.”* For its adoption, we implemented changes to our revenue recognition processes and control activities within them such as development of new entity-wide policies, in-house training, ongoing contract reviews and system changes to accommodate presentation and disclosure requirements. During the most recent fiscal quarter, we added processes and controls for the additional revenue streams acquired, particularly related to the practice management and group purchasing services. We are in the process of evaluating additional processes and controls that may be required.

There were no other changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 147 characters.

Pursuant to the instructions of Item 1A of Form 10-Q, a smaller reporting company is not required to provide the information required by this Item.

Filed Nov 7, 2018.
Source: SEC EDGAR, the filing index for accession 0001493152-18-015353. Last ingested by Listed: Nov 5, 2026, 18:58 ET. No prices; not investment advice.
